Aileron Therapeutics, Inc.: Clinical stage oncology company conducting 3 clinical trials for its lead candidate, ALRN-6924, a first-in-class/best-in-class drug that targets the p53 pathway. ALRN-6924 is from the Stapled peptide platform and is the only clinical drug candidate that binds equipotently to both of the p53 suppressor proteins, MDMX and MDM2. This company has now initiated of a Phase 1 / 1b in Acute Myeloid Leukemia (AML) and a Phase 2a in Peripheral T-Cell Lymphoma.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll
Disease Space
Oncology
Finance
Pre-earnings
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Platform Technology
Website:
Address:
Cambridge, Massachusetts
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.